A Randomized Phase 2, Open-Label Study Of CP-751,871 In Combination With Docetaxel And Docetaxel Alone As A First Line Treatment Of Patients With Advanced Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival
3 years
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A4021008
NCT00678626
April 2009
September 2011
Name | Location |
---|